Qiagen (NYSE:QGEN) is a global provider of sample preparation, molecular testing and bioinformatics solutions used in life sciences research, molecular diagnostics and applied testing. The company develops technologies that help customers isolate and analyze DNA, RNA and other biological materials from blood, tissue and other samples.
Its offerings include laboratory instruments, consumables, assay kits and software. Key product areas include automated sample-processing systems, polymerase chain reaction (PCR) and digital PCR solutions, next-generation sequencing workflows, bioinformatics tools, and diagnostic tests such as QuantiFERON for tuberculosis testing and QIAstat-Dx for syndromic testing. QIAGEN also provides solutions for pharmaceutical research, biopharmaceutical development, academic research, food and animal testing, and forensic applications.
The company was founded in 1984 in Germany as Diagen and has since expanded into a multinational organization serving customers in North America, Europe, Asia and other international markets. QIAGEN is headquartered in Venlo, the Netherlands, with major operations in Germany and a global network of sales, manufacturing and research facilities. Thierry Bernard has served as chief executive officer since 2020.
